David Miller, PhD, is an expert in medicinal chemistry with over 20 years of industry experience. After working in the laboratory, he rose to team leader, group leader, project leader and worked in a portfolio management team. At Inflazome, he has been a key member of the team driving drug candidate IZD174 toward clinical trials, currently expected in 2019. He previously worked for Organon Laboratories, Amedis Therapeutics, Paradigm Therapeutics and Takeda. At Takeda, Dr. Miller led the development of drugs acting upon the central nervous system (CNS), which was accompanied by the development of both a PET tracer and a viable biomarker. He is driven by excellence in pre-clinical science, translation to clinical research and his desire to bring safe and effective products to market to address unmet or poorly met clinical needs. Academically, Dr. Miller has published widely on new methods of organic syntheses and been named an inventor on many patents.